A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)

未提供0 个研究点目标入组 750 人开始时间: 待定

适应症

试验速览

暂无简介。

•Has Lp(a) >= 150 nmol/L.
•Is receiving an optimized and stable dose of statin for >= 30 days with no planned additions, dose changes, or discontinuations through the duration of the study.

•Has a history of homozygous familial hypercholesterolemia (FH), compound heterozygous FH, or double heterozygous FH.
•Has a history of class IV heart failure, severe systolic dysfunction, uncontrolled ventricular arrhythmia, markedly prolonged corrected QT interval, untreated hypertension, or a recent coronary, cerebrovascular, or peripheral ischemic event or arterial revascularization.
•Has human immunodeficiency virus infection, unless the infection is controlled (i.e. undetectable viral load).
•Has an active hepatitis C virus infection or active or chronic hepatitis B virus infection.
•Has a history of nephrotic syndrome.
•Has severe renal insufficiency.
•Has received certain therapies in the prohibited timeframe as specified in the protocol.
•Has active or chronic hepatobiliary or hepatic disease.
•Has poorly controlled Type 1 or Type 2 diabetes.

发起方

未提供